Skip to main content
Premium Trial:

Request an Annual Quote

Seqera Labs Raises $5.5M in Seed Funding

NEW YORK – Life sciences workflow software startup Seqera Labs said Tuesday that it has raised $5.5 million in seed funding. Talis Capital and Speedinvest led the round, with participation from the Chan Zuckerberg Initiative and BoxOne Ventures.

Barcelona, Spain-based Seqera, a spinout of the Centre for Genomic Regulation, develops workflow management software for data pipeline processing, working in multi-cloud environments and facilitating collaboration. Founded in 2018 by the creators of the Nextflow open-source programming framework for DNA analysis, Seqera is built on the Nextflow infrastructure.

Seqera said that its platform supported the collaboration that led to the identification of the Alpha and Delta variants of SARS-CoV-2. The technology currently processes all COVID-19 sequencing data from the UK.

The company claims six of the 10 largest pharmaceutical companies as customers.

"From personalized immunogenic vaccines to new diagnostics, our customers are performing work paramount to our global health," Seqera Labs CEO and cofounder Evan Floden said in a statement. "Joining forces with Speedinvest and Talis Capital provides us with an unparalleled opportunity to grow our reach and serve these customers better."

Arnaud Bakker, principal at Speedinvest, said that the proliferation of DNA sequencing data has necessitated technology such as Nextflow and Seqera. "Seqera's open and cloud-first framework provides an advanced tooling kit allowing organizations to scale complex deployments of data analysis and enable data-driven life sciences solutions," Bakker said.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.